Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label sacubitril/valsartan extension in pediatric heart failure after PANORAMA-HF
2018-004154-25Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sacubitril + valsartan in heart failure (HF) and heart failure with reduced ejection fraction (HFrEF), sponsored by Novartis. Primary endpoints: Number of participants with adverse events and Number of participants with serious adverse events. Started Apr 2019; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure (HF)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2018-004154-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004154-25.